ClinicalTrials.gg
CompletedNCT04957758Updated May 7, 2024Results posted

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

A Phase 2 interventional study of OC-01 (varenicline) nasal spray 1.2 mg/ml and Placebo (vehicle) nasal spray in Neurotrophic Keratopathy, sponsored by Oyster Point Pharma, Inc.. Completed at 31 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray as compared to placebo nasal spray for mean change from baseline in corneal fluorescein staining in subjects with Stage 1 (corneal epithelial hyperplasia/punctate keratopathy) neurotrophic keratopathy (NK) in one or both eyes.

Read the detailed description

Protocol OPP-102 is a Phase 2, multicenter, randomized, controlled, double- masked study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray in subjects with NK. Approximately 100 subjects at least 18 years of age with a physicians' diagnosis of Stage 1 NK as defined by the Mackie Criteria and meeting all other study eligibility criteria will be randomized 1:1 and will receive OC-01 (varenicline)/ nasal spray or placebo nasal spray for 8 weeks three times daily (TID) as follows:

  • OC-01 (varenicline) nasal spray, 1.2 mg/mL
  • Placebo (vehicle control) nasal spray All doses will be delivered as a 50 microliter (µL) nasal spray.
02

Conditions studied

  • Neurotrophic Keratopathy
03

In context

Lead sponsor

Oyster Point Pharma, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.

First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be at least 18 years of age at Visit 1.
  2. Patients with Stage 1 (corneal epithelial hyperplasia/punctate keratopathy) NK in one or both eyes, as defined by the Mackie Criteria.
  3. Evidence of decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet aesthesiometer) in at least 1 corneal quadrant.
  4. Schirmer's test without anesthesia ≥3 mm/ 5 minutes in the affected eye.
  5. If a female is of , they must: use an acceptable means of (acceptable methods of contraception include hormonal - oral, implantable, injectable, or transdermal contraceptives, mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner), and have a negative urine pregnancy test on Day 1.

Exclusion criteria

Exclusion Criteria:

  1. Have Stage 2 or Stage 3 NK affecting one or both eyes.
  2. Have ocular or Stevens-Johnson syndrome.
  3. Have any active ocular infection (COVID-19 conjunctivitis, bacterial, viral, fungal, or protozoal) or active ocular inflammation not related to NK in the affected eye.
  4. Be currently receiving autologous serum tears, amniotic membrane, cenegermin, fresh frozen plasma or cord blood derivative tears.
  5. Have severe blepharitis and/or severe meibomian gland disease in the study eye.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
113 participants (actual)

Study arms

  • Active comparator
    OC-01 (varenicline) nasal spray, 1.2 mg/mL

    OC-01 (varenicline) nasal spray, 1.2 mg/mL

    Drug: OC-01 (varenicline) nasal spray 1.2 mg/ml

  • Placebo comparator
    Placebo (vehicle control) nasal spray

    Placebo (vehicle control) nasal spray

    Drug: Placebo (vehicle) nasal spray

Interventions

  • DrugOC-01 (varenicline) nasal spray 1.2 mg/ml

    Drug page: Varenicline

    OC-01

  • DrugPlacebo (vehicle) nasal spray

    Placebo (vehicle)

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Corneal Fluorescein Staining

    Corneal Fluorescein Staining was measured utilizing the Modified Oxford Grading scale. Scores range from a minimum of 0 (no staining) to a maximum of 5. A higher score indicates a worse outcome. The study eye is defined as the eye with the worst staining grade (if both eyes are eligible).

    Time frame: 8 weeks

Secondary outcomes

  1. Mean Change From Baseline in Visual Acuity at Week 8

    Best Corrected Visual Acuity was assessed based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. ETDRS letters score range from 0 to 100 letters at each assessment. A higher score in ETDRS letters indicates a better outcome. A positive change from Baseline in ETDRS letter score indicates an improvement in visual acuity.

    Time frame: 8 weeks

07

Results

Posted May 7, 2024

Participant flow

Participant flow — Overall Study
MilestoneOC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal Spray
Started5360
Completed4855
Not completed55
Withdrew: Adverse event10
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject42
Withdrew: Protocol violation01

Outcome measures

PrimaryMean Change From Baseline in Corneal Fluorescein Staining

Corneal Fluorescein Staining was measured utilizing the Modified Oxford Grading scale. Scores range from a minimum of 0 (no staining) to a maximum of 5. A higher score indicates a worse outcome. The study eye is defined as the eye with the worst staining grade (if both eyes are eligible).

Time frame:
8 weeks
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Corneal Fluorescein Staining
score on a scaleOC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal Spray
Mean Change From Baseline in Corneal Fluorescein Staining-0.6 ± 0.17-0.9 ± 0.15
SecondaryMean Change From Baseline in Visual Acuity at Week 8

Best Corrected Visual Acuity was assessed based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. ETDRS letters score range from 0 to 100 letters at each assessment. A higher score in ETDRS letters indicates a better outcome. A positive change from Baseline in ETDRS letter score indicates an improvement in visual acuity.

Time frame:
8 weeks
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Visual Acuity at Week 8
score on a scaleOC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal Spray
Mean Change From Baseline in Visual Acuity at Week 80.6 ± 1.151.5 ± 1.03

Adverse events

Collected over Adverse Events were collected at the time of informed consent until the last study visit at 6 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL0/54 (0%)5/54 (9.3%)39/54 (72.2%)
Placebo (Vehicle Control) Nasal Spray0/58 (0%)3/58 (5.2%)34/58 (58.6%)
Most frequent serious events
Most frequent serious events
EventOC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal Spray
Infective Exacerbation of bronchiectasisInfections and infestations1/540/58
PyelonephritisInfections and infestations1/540/58
Skin InfectionInfections and infestations1/540/58
Femur FractureInjury, poisoning and procedural complications1/540/58
Renal NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/540/58
Large Intestinal ObstructionGastrointestinal disorders0/541/58
COVID-19Infections and infestations0/541/58
FallInjury, poisoning and procedural complications0/541/58
Most frequent other events
Showing 10 of 76
Most frequent other events
EventOC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal Spray
SneezingRespiratory, thoracic and mediastinal disorders30/546/58
Throat IrritationRespiratory, thoracic and mediastinal disorders6/540/58
Nasal mucosal disorderRespiratory, thoracic and mediastinal disorders2/545/58
Corneal epithelium defectEye disorders4/541/58
Instillation Site IrritationGeneral disorders4/542/58
Urinary Tract InfectionInfections and infestations3/542/58
PainGeneral disorders0/543/58
Eye IrritationEye disorders2/541/58
Eye PainEye disorders2/541/58
NauseaGastrointestinal disorders2/540/58

Baseline characteristics

Age, Continuous
Age, Continuous(years)OC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal SprayTotal
Mean65.3 ± 14.4861.5 ± 16.3363.3 ± 15.54
Sex: Female, Male
Sex: Female, Male(Participants)OC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal SprayTotal
Female414788
Male121325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal SprayTotal
Hispanic or Latino91423
Not Hispanic or Latino444589
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal SprayTotal
American Indian or Alaska Native011
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American4711
White475097
More than one race000
Unknown or Not Reported202
Corneal Fluorescein staining Score
Corneal Fluorescein staining Score(units on a scale)OC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal SprayTotal
Mean2.29 ± 1.0172.17 ± 1.0282.23 ± 1.020
Best Correct Visual Acuity (Letters)
Best Correct Visual Acuity (Letters)(Number of letters)OC-01 (Varenicline) Nasal Spray, 1.2 mg/mLPlacebo (Vehicle Control) Nasal SprayTotal
Mean75.4 ± 14.4275.9 ± 18.5475.7 ± 16.61
08

Study locations

31 sites
  • Dothan Alabama
    Dothan, Alabama 36301, United States
  • Irvine, California
    Irvine, California 92697, United States
  • Los Angeles California
    Los Angeles, California 90095, United States
  • Mission Hills California
    Mission Hills, California 91345, United States
  • Aurora Colorado
    Aurora, Colorado 80045, United States
  • Littleton, Colorado
    Littleton, Colorado 80120, United States
  • Longmont, Colorado
    Longmont, Colorado 80503, United States
  • Danbury, Connecticut
    Danbury, Connecticut 06810, United States
  • Brandon Florida
    Brandon, Florida 33511, United States
  • Brandon, Florida
    Brandon, Florida 33511, United States
  • Jacksonville Florida
    Jacksonville, Florida 32256, United States
  • Miami Florida
    Miami, Florida 33136, United States
  • Atlanta, Georgia
    Atlanta, Georgia 30339, United States
  • Hoffman Estates, Illinois
    Hoffman Estates, Illinois 60169, United States
  • Urbana Illinois
    Urbana, Illinois 61801, United States
  • Union Kentucky
    Edgewood, Kentucky 41017, United States
  • Louisville KY
    Louisville, Kentucky 40206, United States
  • Bowie, Maryland
    Bowie, Maryland 20716, United States
  • Boston Massachusetts
    Boston, Massachusetts 02114, United States
  • Kansas City Missouri
    Kansas City, Missouri 64111, United States
  • Henderson Nevada
    Henderson, Nevada 89052, United States
  • Bloomfield, New Jersey
    Bloomfield, New Jersey 07003, United States
  • Dover New Jersey
    Dover, New Jersey 07801, United States
  • Babylon New York
    Babylon, New York 11702, United States
  • New York NY
    New York, New York 10029, United States
  • York, Pennsylvania
    York, Pennsylvania 17408, United States
  • Houston Texas
    Houston, Texas 77030, United States
  • Katy, Texas
    Katy, Texas 77494, United States
  • San Antonio Texas
    San Antonio, Texas 78229, United States
  • Lynchburg Virginia
    Lynchburg, Virginia 24502, United States
  • Seattle Washington
    Seattle, Washington 98119, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jan 2023, 19 months.

Results were first posted in May 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2021
First posted
Jul 12, 2021
StartActual
Jun 17, 2021
Primary completionActual
Jan 27, 2023
CompletionActual
Apr 28, 2023
Results first posted
May 7, 2024
Last update
May 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04957758
Responsible party
Sponsor
First posted
Jul 12, 2021
Start date
Jun 17, 2021
Primary completion
Jan 27, 2023
Completion
Apr 28, 2023
Results posted
May 7, 2024
Last update
May 7, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion